Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions
Interna’s MNM molecules will be integrated with targeting approaches for enhancing functional activity.
Drug Development
Nucleai and Sirona Dx to provide new proteomics solution for pharma companies
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
Adcendo secures $75m in Series C funding for ADC development
Lilly to acquire CrossBridge Bio for up to $300m
Travere Therapeutics gains FDA approval for sparsentan in FSGS
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority
Telix and Regeneron sign $4.3bn deal to co-develop radiopharmaceutical therapies
